MarketLens

What is Krazati, and Where Does it Stand Today

4 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Why is the Low-Code Automation Market Exploding, and Where Does Appian Fit In

5 months ago

Why is Roku's Stock Up Today, and What's Driving the Rally

5 months ago

What is Pfizer's Braftovi and Why Does it Matter for Investors

6 months ago

What is Seagate Technology Holdings and Why Does it Matter Now

4 months ago

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Zipalertinib plus chemotherapy showed a 6-month median progression-free survival benefit versus chemotherapy alone in first-line EGFR exon 20 insertion NSCLC, per Phase 3 REZILIENT3 data presented at ...

CGEM

Stock News•1 months ago

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Eli Lilly's olomorasib received FDA Breakthrough Therapy designation for previously treated KRAS G12C-mutant advanced pancreatic cancer, after showing potential as a next-generation inhibitor. The des...

LLY

Stock News•2 months ago

Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win

Kura Oncology positions ziftomenib as an AML combination backbone, supported by high remission rates and tolerability data. A robust cash position from Kyowa Kirin payments funds the pivotal KOMET-017...

KURA

Breaking News

Low Volatility Factor

Startup Funding

Top Headlines

View More →

Stock News•29 minutes ago

Samsung backs Nvidia AI chip rival in $230 million funding round as GPU alternatives boom

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Microsoft Just Made a Move That Could Put More Pressure on Its Azure Business. Here's Why It Could Turn Out Great for the Stock

Stock News•1 hour ago

Nasdaq Tests Key Level On AI Warnings Ahead Of Fed Meeting; Nvidia, Sandisk, Micron Tumble

Stock News•2 hours ago

What is Krazati, and Where Does it Stand Today

Exclusive Content for Pro Members

Related Articles

Why is the Low-Code Automation Market Exploding, and Where Does Appian Fit In

Why is Roku's Stock Up Today, and What's Driving the Rally

What is Pfizer's Braftovi and Why Does it Matter for Investors

What is Seagate Technology Holdings and Why Does it Matter Now

Category

You may also like

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Samsung backs Nvidia AI chip rival in $230 million funding round as GPU alternatives boom

Why the Market Dipped But Microsoft (MSFT) Gained Today

Microsoft Just Made a Move That Could Put More Pressure on Its Azure Business. Here's Why It Could Turn Out Great for the Stock

Nasdaq Tests Key Level On AI Warnings Ahead Of Fed Meeting; Nvidia, Sandisk, Micron Tumble

Trump phones Nvidia's Huang at All-In Summit, calls data center opposition a ‘hoax'